Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. raised its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 9.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 851,512 shares of the company's stock after buying an additional 76,720 shares during the period. Victory Capital Management Inc. owned 1.49% of Olema Pharmaceuticals worth $10,167,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in Olema Pharmaceuticals in the 2nd quarter worth $34,753,000. Great Point Partners LLC bought a new position in shares of Olema Pharmaceuticals during the second quarter valued at $8,622,000. Candriam S.C.A. grew its stake in shares of Olema Pharmaceuticals by 199.9% in the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company's stock worth $11,454,000 after acquiring an additional 705,655 shares during the period. Janus Henderson Group PLC grew its stake in shares of Olema Pharmaceuticals by 74.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company's stock valued at $13,817,000 after purchasing an additional 521,562 shares during the period. Finally, Affinity Asset Advisors LLC bought a new stake in Olema Pharmaceuticals in the 2nd quarter worth approximately $2,976,000. Institutional investors own 91.78% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on OLMA. JPMorgan Chase & Co. dropped their target price on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, November 13th. Finally, Oppenheimer restated an "outperform" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $27.00.

Olema Pharmaceuticals Trading Down 5.0 %

NASDAQ:OLMA traded down $0.41 during midday trading on Thursday, hitting $7.87. 1,230,786 shares of the company were exchanged, compared to its average volume of 735,654. Olema Pharmaceuticals, Inc. has a fifty-two week low of $7.68 and a fifty-two week high of $16.77. The company has a market capitalization of $450.95 million, a PE ratio of -3.55 and a beta of 2.02. The company has a fifty day simple moving average of $11.77 and a 200 day simple moving average of $11.93.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.